Ferya Karadağ Yalçın
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ferya Karadağ Yalçın has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Erhan Eser
Manisa Celal Bayar University
4 shared publications - Sinem Akçalı
Manisa Celal Bayar Univ, Dept Med Microbiol, Fac Med, Manisa, Turkey
4 shared publications - Şebnem Şenol Akar
Manisa Celal Bayar Univ, Dept Infect Dis & Clin Microbiol, Fac Med, Manisa, Turkey
4 shared publications - Kübra Çiçek
Hatay Dörtyol İlçe Sağlık Müdürlüğü
3 shared publications - Pınar Erbay Dündar
MANİSA CELÂL BAYAR ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, HALK SAĞLIĞI ANABİLİM DALI
3 shared publications - Zeynep Ceyda Buran
Manisa Celal Bayar Univ, Dept Publ Hlth, Fac Med, Manisa, Turkey
3 shared publications
Latest Publications
- 15 April 2023
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 57 (2) , 238-251
Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers
This study was aimed to determine the efficacy of homologous (only CoronaVac or only Pfizer-BioN- Tech) and heterologous (CoronaVac and Pfizer-BioNTech) vaccines during the period when the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant was dominant in T0rkiye. Coro- navirus disease-2019 (COVID-2019) infection was confirmed by reverse transcriptase polymerase chain reaction and data on vaccination status against COVID-19 were evaluated during the period of 15 January 2022-1 May 2022 when the SARS-CoV-2 Omicron variant was dominant among 1854 employees fol- lowed in the SARS-CoV-2 Vaccine Cohort of Manisa Celal Bayar University (MCBU) Hospital Health Work-ers. Two separate reference groups were used in the evaluation of vaccine efficacy: those who were never vaccinated and those who received only two doses of CoronaVac. The efficacy of homologous and heter- ologous vaccine models was evaluated with relative risks and attributable risk percentages. MS Excel, SPSS 23.0 and STATA 14.1 package programs were used for statistical analysis. The mean age of the participants was 36.6 +/- 10.0. During the period from January 15th to May 1st 2022, 372 hospital workers were infected with COVID-19. Taking the never vaccinated as the reference group, the most effective model was found to be only the three or more doses of the Pfizer-BioNTech primary vaccination model (85.8%, 95% CI= 40.7-96.6). Models consisting of a single dose of CoronaVac (6.5%, 95% CI=-56.3-44.2) or a single dose of Pfizer-BioNTech (17.7%, 95% CI=-30.2-48.0) booster dose administered after two doses of primary CoronaVac vaccination was not found to be effective against the SARS-CoV-2 Omicron variant. When only two doses of primary CoronaVac vaccination model was taken as the reference group, the model consist-ing of two doses CoronaVac followed by two Pfizer-BioNTech booster doses was effective as 38.4% (95% CI= 15.4-55.3), whereas three doses of Pfizer-BioNTech booster model was effective as 56.4% (95% CI= 33.9-71.3). To conclude, none of the models other than the homologous or heterologous vaccine models containing at least three doses of Pfizer-BioNTech vaccine were effective compared to those unvaccinated. Compared with those who received only two doses of primary Coronavac, models with at least three dos-es of Pfizer-BioNTech reminder doses were more effective against the Omicron variant than other models.
- 15 April 2023
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 57 (2) , 238-251
Efficacy of Homologous and Heterologous Vaccine Applications on SARS-CoV-2 Omicron Variant: Cohort of Manisa Celal Bayar University Healthcare Workers
This study was aimed to determine the efficacy of homologous (only CoronaVac or only Pfizer-BioN- Tech) and heterologous (CoronaVac and Pfizer-BioNTech) vaccines during the period when the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant was dominant in T0rkiye. Coro- navirus disease-2019 (COVID-2019) infection was confirmed by reverse transcriptase polymerase chain reaction and data on vaccination status against COVID-19 were evaluated during the period of 15 January 2022-1 May 2022 when the SARS-CoV-2 Omicron variant was dominant among 1854 employees fol- lowed in the SARS-CoV-2 Vaccine Cohort of Manisa Celal Bayar University (MCBU) Hospital Health Work-ers. Two separate reference groups were used in the evaluation of vaccine efficacy: those who were never vaccinated and those who received only two doses of CoronaVac. The efficacy of homologous and heter- ologous vaccine models was evaluated with relative risks and attributable risk percentages. MS Excel, SPSS 23.0 and STATA 14.1 package programs were used for statistical analysis. The mean age of the participants was 36.6 +/- 10.0. During the period from January 15th to May 1st 2022, 372 hospital workers were infected with COVID-19. Taking the never vaccinated as the reference group, the most effective model was found to be only the three or more doses of the Pfizer-BioNTech primary vaccination model (85.8%, 95% CI= 40.7-96.6). Models consisting of a single dose of CoronaVac (6.5%, 95% CI=-56.3-44.2) or a single dose of Pfizer-BioNTech (17.7%, 95% CI=-30.2-48.0) booster dose administered after two doses of primary CoronaVac vaccination was not found to be effective against the SARS-CoV-2 Omicron variant. When only two doses of primary CoronaVac vaccination model was taken as the reference group, the model consist-ing of two doses CoronaVac followed by two Pfizer-BioNTech booster doses was effective as 38.4% (95% CI= 15.4-55.3), whereas three doses of Pfizer-BioNTech booster model was effective as 56.4% (95% CI= 33.9-71.3). To conclude, none of the models other than the homologous or heterologous vaccine models containing at least three doses of Pfizer-BioNTech vaccine were effective compared to those unvaccinated. Compared with those who received only two doses of primary Coronavac, models with at least three dos-es of Pfizer-BioNTech reminder doses were more effective against the Omicron variant than other models.
- 25 April 2022
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 56 (2) , 274-287
Sağlık Çalışanları SARS-CoV-2 Hasta Kohordunda Antikor Sürdürülebilirliği
In this study, it was aimed to evaluate one-year follow-up of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) specific antibodies formed against the virus binding site, in a coronavirus disease-2019 (COVID-19) positive case cohort (n= 413) between the period March 2020 to December 2020 in Manisa Celal Bayar University Hospital, until July 2021. SARS-CoV-2 antibodies were determined by the chemiluminescent enzyme immunoassay (CLIA) method. Values of 1.0 and above were considered positive. Chi-square tests and Joinpoint regression analysis (version 4.7.0) were used in the statistical analyses. The mean age of the participants was 34.9 +/- 9.3 and 60.2% of them were women. Between 21-30 days after the diagnosis of COVID-19, total antibody level was above the threshold value in 72.2% (n= 126) of the participants, while this rate increased to 79.1% (n= 240) in 31-60 day interval. In the following period, this rate decreased to 38.8% (n= 108) in days 211st to 240th. Antibody response could not be detected in 76 (20.7%) of 367 employees who have initially been followed up. The percentage of total antibody positivity prevalence ranged from 98.9% to 96.1% in the 31-210th day after diagnosis, in the follow-up of 291 employees whose total antibody positivity was detected after diagnosis. According to the results of the Joinpoint regression analysis, after the diagnosis of COVID-19, the curve showing the percentage of antibody positivity was broken at two points: The first breaking point was observed in 181-210th days (6-7 months) (p= 0.069), and the second breaking point was in 271-300th days (9-10 months) (p< 0.001). As a result, the highest antibody positivity rates were detected after the 30th day of the disease onset and antibody positivity was maintained in the first seven months after diagnosis; the antibody positivity rate decreased to 25% at the end of the first year.
- 25 April 2022
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 56 (2) , 274-287
Sağlık Çalışanları SARS-CoV-2 Hasta Kohordunda Antikor Sürdürülebilirliği
In this study, it was aimed to evaluate one-year follow-up of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) specific antibodies formed against the virus binding site, in a coronavirus disease-2019 (COVID-19) positive case cohort (n= 413) between the period March 2020 to December 2020 in Manisa Celal Bayar University Hospital, until July 2021. SARS-CoV-2 antibodies were determined by the chemiluminescent enzyme immunoassay (CLIA) method. Values of 1.0 and above were considered positive. Chi-square tests and Joinpoint regression analysis (version 4.7.0) were used in the statistical analyses. The mean age of the participants was 34.9 +/- 9.3 and 60.2% of them were women. Between 21-30 days after the diagnosis of COVID-19, total antibody level was above the threshold value in 72.2% (n= 126) of the participants, while this rate increased to 79.1% (n= 240) in 31-60 day interval. In the following period, this rate decreased to 38.8% (n= 108) in days 211st to 240th. Antibody response could not be detected in 76 (20.7%) of 367 employees who have initially been followed up. The percentage of total antibody positivity prevalence ranged from 98.9% to 96.1% in the 31-210th day after diagnosis, in the follow-up of 291 employees whose total antibody positivity was detected after diagnosis. According to the results of the Joinpoint regression analysis, after the diagnosis of COVID-19, the curve showing the percentage of antibody positivity was broken at two points: The first breaking point was observed in 181-210th days (6-7 months) (p= 0.069), and the second breaking point was in 271-300th days (9-10 months) (p< 0.001). As a result, the highest antibody positivity rates were detected after the 30th day of the disease onset and antibody positivity was maintained in the first seven months after diagnosis; the antibody positivity rate decreased to 25% at the end of the first year.
- Open Access
- 1 April 2022
- Published by Turkish Journal of Public Health in Türkiye Halk Sağlığı Dergisi
- Vol. 20 (1) , 117-128
Türkiye’de bir üçüncü basamak hastanede sağlık çalışanlarında SARS-CoV-2 seroprevalansı
Objective: The aim of this study is to investigate the previous four months (March-July 2020) SARS-CoV-2 infection rate, seroprevalence and the variables affecting these in HCWs in a university hospital. Methods: The present study is a SARS-CoV-2 seroprevalence study on HCWs working in a tertiary hospital during the first stage (March-July 2020) of the outbreak in Turkey. The presence of IgM and IgG antibodies against the spike structure of the virus was investigated by the chemiluminescent enzyme immunoassay (CLIA) method using the commercial antibody kit (COV2T, Siemens®, Tarrytown, NY, US). Participants’ socio-demographic characteristics, health status, lifestyle, risky occupational and social and personal protective equipment (PPE) usage were independent variables of the study. Chi-square test and Fisher’s exact test were used in univariate analyzes, and accepted type 1 error value was 0.05. The analyzes were made using the SPSS 23.0 package program. Results: 1177 out of a total of 1702 health workers participated in the study. Participation rate was 69.1% . The mean age of the study group was 35.3 ± 9.8 and 62.7% were females. SARS-CoV-2 infection rate detected by nucleic acid amplification test (NAAT-PCR) or antibody test (Elisa) was (18/1177) 1.5%; The seroprevalence of SARS-CoV-2 was 1.01%. 17% of the entire SARS-CoV-2 cases were asymptomatic. The highest infection prevalence was significantly higher in auxiliary health workers (3.7%) compared to other groups. The presence of symptoms HCW’s and their family members that did not exist before in the last 15 days, being overweight or obese and consulting as contacted person in survelliance unit were significantly related to having SARS-CoV-2 infection (p
- 1 April 2022
- Published by Turkish Journal of Public Health in Türkiye Halk Sağlığı Dergisi
- Vol. 20 (1) , 117-128
Open AccessTürkiye’de bir üçüncü basamak hastanede sağlık çalışanlarında SARS-CoV-2 seroprevalansı
Objective: The aim of this study is to investigate the previous four months (March-July 2020) SARS-CoV-2 infection rate, seroprevalence and the variables affecting these in HCWs in a university hospital. Methods: The present study is a SARS-CoV-2 seroprevalence study on HCWs working in a tertiary hospital during the first stage (March-July 2020) of the outbreak in Turkey. The presence of IgM and IgG antibodies against the spike structure of the virus was investigated by the chemiluminescent enzyme immunoassay (CLIA) method using the commercial antibody kit (COV2T, Siemens®, Tarrytown, NY, US). Participants’ socio-demographic characteristics, health status, lifestyle, risky occupational and social and personal protective equipment (PPE) usage were independent variables of the study. Chi-square test and Fisher’s exact test were used in univariate analyzes, and accepted type 1 error value was 0.05. The analyzes were made using the SPSS 23.0 package program. Results: 1177 out of a total of 1702 health workers participated in the study. Participation rate was 69.1% . The mean age of the study group was 35.3 ± 9.8 and 62.7% were females. SARS-CoV-2 infection rate detected by nucleic acid amplification test (NAAT-PCR) or antibody test (Elisa) was (18/1177) 1.5%; The seroprevalence of SARS-CoV-2 was 1.01%. 17% of the entire SARS-CoV-2 cases were asymptomatic. The highest infection prevalence was significantly higher in auxiliary health workers (3.7%) compared to other groups. The presence of symptoms HCW’s and their family members that did not exist before in the last 15 days, being overweight or obese and consulting as contacted person in survelliance unit were significantly related to having SARS-CoV-2 infection (p
- 18 October 2021
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 55 (4) , 519-538
Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers
In this study, it was aimed to prospectively evaluate the efficacy, side effects and seroconversion data of inactive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), CoronaVac (R) (Sinovac, China) vaccine in healthcare workers. A total of 1053 healthcare workers who were initially seronegative (COV2T (R) SARS-CoV-2 Total Siemens, USA) and vaccinated with inactivated SARS-CoV-2 were included in the study. Quantitative IgG antibodies (ADVIA Centaur (R) SARS-CoV-2 IgG, Siemens, USA) were investigated 28 days after the first vaccine (n=939) and the second vaccine (n=771). In addition, neutralizing antibodies were evaluated via "enzyme linked immunosorbent assay (ELISA)" test (ACE2-RBD Neutralization Assay, Dia-Pro, Italy) 28 days after the first vaccine. Antibody response of the vaccine was evaluated statistically by univariate (Chi-square, Fisher's exact test, Student's t test, Mann-Whitney U, one-way ANOVA and Kruskall Wallis ANOVA tests) analysis and linear regression models. The consistency between quantitative IgG test and neutralizing antibody test was also evaluated in blood samples taken 28 days after second vaccination. Statistical analysis was determined in logarithmically transformed data with statistical analysis with SPSS 23.0 and Stata, and type 1 error level was accepted as 0.05. At least one side effect was reported by 31.3% and 26.8% of the participants after the first and second vaccine, respectively. The most frequent side effect was pain at the injection site with a frequency of 20.4% vs 21.7%. The frequency of applying to a health center due to side effects was 1.0% after the first vaccine and 0.8% after the second vaccine. The percentage of those who produced sufficient quantitative IgG was found as 25.3% (95% CI=22.5-28.1) 28 days after the first vaccine and 97.9% (95% CI=96.9198.93) after the second vaccine. Neutralizing test antibody positivity was found as 97.7% 28 days after the second vaccine. In univariate analysis, the characteristics that significantly increased the quantitative IgG response against inactivated SARS-CoV-2 vaccine were young age (p<0.01), female gender (p< 0.01), being a non-smoker (p<0.001), not having a chronic disease (p=0.019), having had the flu vaccine this year (p=0.012), not being overweight or obese (p=0.020), and having a SARS-CoV2 infection prior to vaccination (p<0.001). In addition, allied health personnel showed significantly lower antibody responses than the other workers (p<0.001). Multiple linear regression models revealed that, female gender, younger age, smoking and previous COVID-19 polymerase chain reaction test positivity significantly affected the quantitative IgG response after vaccination. A 99% agreement was found between the ELISA-based neutralizing antibody test and the quantitative IgG test (Kappa p=0.783) performed on the 28th day after the second vaccination. CoronaVac (R) provides adequate antibody response in 25% of healthcare workers aged 18-64, after 28 days from a single vaccine, and 97% after 28 days from the second vaccine. Antibody response was significantly higher in younger ages, women, non-smokers, and those who had previously encountered SARS-CoV-2. Phase 3 and phase 4 results are needed to show effectiveness of this vaccine in real life.
- 18 October 2021
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 55 (4) , 519-538
Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers
In this study, it was aimed to prospectively evaluate the efficacy, side effects and seroconversion data of inactive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), CoronaVac (R) (Sinovac, China) vaccine in healthcare workers. A total of 1053 healthcare workers who were initially seronegative (COV2T (R) SARS-CoV-2 Total Siemens, USA) and vaccinated with inactivated SARS-CoV-2 were included in the study. Quantitative IgG antibodies (ADVIA Centaur (R) SARS-CoV-2 IgG, Siemens, USA) were investigated 28 days after the first vaccine (n=939) and the second vaccine (n=771). In addition, neutralizing antibodies were evaluated via "enzyme linked immunosorbent assay (ELISA)" test (ACE2-RBD Neutralization Assay, Dia-Pro, Italy) 28 days after the first vaccine. Antibody response of the vaccine was evaluated statistically by univariate (Chi-square, Fisher's exact test, Student's t test, Mann-Whitney U, one-way ANOVA and Kruskall Wallis ANOVA tests) analysis and linear regression models. The consistency between quantitative IgG test and neutralizing antibody test was also evaluated in blood samples taken 28 days after second vaccination. Statistical analysis was determined in logarithmically transformed data with statistical analysis with SPSS 23.0 and Stata, and type 1 error level was accepted as 0.05. At least one side effect was reported by 31.3% and 26.8% of the participants after the first and second vaccine, respectively. The most frequent side effect was pain at the injection site with a frequency of 20.4% vs 21.7%. The frequency of applying to a health center due to side effects was 1.0% after the first vaccine and 0.8% after the second vaccine. The percentage of those who produced sufficient quantitative IgG was found as 25.3% (95% CI=22.5-28.1) 28 days after the first vaccine and 97.9% (95% CI=96.9198.93) after the second vaccine. Neutralizing test antibody positivity was found as 97.7% 28 days after the second vaccine. In univariate analysis, the characteristics that significantly increased the quantitative IgG response against inactivated SARS-CoV-2 vaccine were young age (p<0.01), female gender (p< 0.01), being a non-smoker (p<0.001), not having a chronic disease (p=0.019), having had the flu vaccine this year (p=0.012), not being overweight or obese (p=0.020), and having a SARS-CoV2 infection prior to vaccination (p<0.001). In addition, allied health personnel showed significantly lower antibody responses than the other workers (p<0.001). Multiple linear regression models revealed that, female gender, younger age, smoking and previous COVID-19 polymerase chain reaction test positivity significantly affected the quantitative IgG response after vaccination. A 99% agreement was found between the ELISA-based neutralizing antibody test and the quantitative IgG test (Kappa p=0.783) performed on the 28th day after the second vaccination. CoronaVac (R) provides adequate antibody response in 25% of healthcare workers aged 18-64, after 28 days from a single vaccine, and 97% after 28 days from the second vaccine. Antibody response was significantly higher in younger ages, women, non-smokers, and those who had previously encountered SARS-CoV-2. Phase 3 and phase 4 results are needed to show effectiveness of this vaccine in real life.